
Conclusion
Catheter ablation is an effective treatment for AF. Pulmonary
vein isolation remains the cornerstone of AF ablation procedures,
with considerable effort having been directed towards developing
technologies to achieve safer and more durable lesions. Ongoing
research is being invested in studying ablation strategies to
improve outcomes in various AF populations.
References
1. Wolf PA, Mitchell JB, Baker CS, et al. Impact of AF on mortality, stroke, and
medical costs. Arch Intern Med 1998;158(3):229–34.
2. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and
pathophysiology of AF: relationships among clinical features, epidemiology,
and mechanisms. Circ Res 2014;114(9):1453–68.
3. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an
economic analysis of AF in the UK. Heart 2004;90(3):286–92.
4. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-
morbidities of AF in a privately insured population. Current medical research
and opinion 2005;21(10):1693–9.
5. Reynolds MR, Essebag V, Zimetbaum P, et al. Healthcare resource utilization
and costs associated with recurrent episodes of AF: the FRACTAL registry. J
Cardiovasc Electrophysiol 2007;18(6):628–33.
6. Gillis AM, Verma A, Talajic M, et al. Canadian Cardiovascular Society
AF guidelines 2010: rate and rhythm management. Can J Cardiol
2011;27(1):47–59.
7. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of AF.
Canadian Trial of AF Investigators. N Engl J Med 2000;342(13):913–20.
8. Singh SN, Singh BN, Reda DJ, et al. Comparison of sotalol versus
amiodarone in maintaining stability of sinus rhythm in patients with AF
(Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol
2003;92(4):468–72.
9. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol
1998;82(4A):49I–57I.
10. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for
persistent AF: a meta-analysis. Mayo Clin Proc 2009;84(3):234–42.
11. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter
substrate ablation for high-risk patients with AF. J Am Coll Cardiol
2008;51(8):843–9.
12. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus
rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up
Investigation of Rhythm Management (AFFIRM) Study. Circulation
2004;109(12):1509–13.
13. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential
pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal
AF: the APAF Study. J Am Coll Cardiol 2006;48(11):2340–7.
14. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation
vs antiarrhythmic drugs as first-line treatment of symptomatic AF: a
randomized trial. JAMA 2005;293(21):2634–40.
15. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic
drugs for AF: the A4 study. Circulation 2008;118(24):2498–505.
16. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation
for chronic AF. N Engl J Med 2006;354(9):934–41.
17. Packer DL, Irwin JM, Champagne J, et al. Cryoballoon ablation of pulmonary
veins for paroxysmal atrial fibrillation: first results of the North American
Arctic Front STOP-AF pivotal trial. J Am Coll Cardiol 2010;55:E3015–6.
18. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, et al. A
randomized clinical trial of the efficacy of radiofrequency catheter
ablation and amiodarone in the treatment of symptomatic AF. Journal of
the Medical Association of Thailand = Chotmaihet thangphaet 2003;86
Suppl 1:S8–16.
19. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in
patients with drug-refractory AF: a prospective, multi-centre, randomized,
controlled study (Catheter Ablation For The Cure Of AF Study). Eur Heart J
2006;27(2):216–21.
20. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug
therapy and radiofrequency catheter ablation in patients with paroxysmal AF:
a randomized controlled trial. JAMA 2010;303(4):333–40.
21. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation
for AF have long-term rates of death, stroke, and dementia similar to patients
without AF. J Cardiovasc Electrophysiol 2011;22(8):839–45.
22. Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for
the maintenance of sinus rhythm in patients with AF: a meta-analysis
of randomized, controlled trials. Circ Arrhythm Electrophysiol
2009;2(6):626–33.
23. Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after
ablation of AF the impact of recurrence, symptom relief, and placebo effect. J
Am Coll Cardiol 2010;55(21):2308–16.
24. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for
persistent AF. N Engl J Med 2015;372(19):1812–22.
25. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/
SOLAECE expert consensus statement on catheter and surgical ablation of
AF. Europace 2018;20(1):e1–e160.
26. Reddy VY, Shah D, Kautzner J, et al. The relationship between contact force
and clinical outcome during radiofrequency catheter ablation of AF in the
TOCCATA study. Heart Rhythm 2012;9(11):1789–95.
27. Neuzil P, Reddy VY, Kautzner J, et al. Electrical reconnection after pulmonary
vein isolation is contingent on contact force during initial treatment: results
from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6(2):327–33.
28. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, Controlled Trial
of the Safety and Effectiveness of a Contact Force-Sensing Irrigated
Catheter for Ablation of Paroxysmal AF: Results of the TactiCath Contact
Force Ablation Catheter Study for AF (TOCCASTAR) Study. Circulation
2015;132(10):907–15.
29. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with
a contact force sensing catheter: results of the prospective, multicenter
SMART-AF trial. J Am Coll Cardiol 2014;64(7):647–56.
30. Calkins H, Reynolds MR, Spector P, et al. Treatment of AF with
antiarrhythmic drugs or radiofrequency ablation: two systematic literature
reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2(4):349–61.
31. Andrade JG, Khairy P, Dubuc M. Catheter cryoablation: biology and clinical
uses. Circ Arrhythm Electrophysiol 2013;6(1):218–27.
32. Pandya B, Sheikh A, Spagnola J, et al. Safety and efficacy of second-
generation versus first-generation cryoballoons for treatment of AF: a meta-
analysis of current evidence. JInterv Card Electrophysiol 2015.
33. Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon
ablation for AF: a systematic review of published studies. Heart Rhythm
2011;8(9):1444–51.
34. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or Radiofrequency
Ablation for Paroxysmal AF. N Engl J Med 2016;374(23):2235–45.
35. Buiatti A, von Olshausen G, Barthel P, et al. Cryoballoon vs. radiofrequency
ablation for paroxysmal AF: an updated meta-analysis of randomized and
observational studies. Europace 2017;19(3):378–84.
36. Andrade JG, Deyell MW, Badra M, et al. Randomized clinical trial of
cryoballoon versus irrigated radio frequency catheter ablation for atrial
fibrillation-the effect of double short versus standard exposure cryoablation
duration during pulmonary vein isolation (CIRCA-DOSE): methods and
rationale. BMJ Open 2017;7(10):e017970.
37. Padfield GJ, Steinberg C, Swampillai J, et al. Progression of paroxysmal to
persistent AF: 10-year follow-up in the Canadian Registry of AF. Heart
Rhythm 2017;14(6):801–7.
38. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency
ablation as initial therapy in paroxysmal AF. N Engl J Med
2012;367(17):1587–95.
Canadian Journal of General Internal Medicine
8 Volume 13, Special Issue 1, 2018
What is the Latest on Catheter Ablation of Atrial Fibrillation?